Introduction: Eclampsia is one of the leading causes of maternal mortality. Magnesium sulfate (MgSO 4 ) can be a drug for its management.
INTRODUCTION
Pregnancy and motherhood is gift of nature and the most beautiful event which occur in a women's life. But sometimes this gift is wrapped with some complications also which can endanger her life. Eclampsia is one of the most dreaded complications of toxemia of pregnancy, which puts the life of both mother and fetus at stake. Over a period of time, though much has been understood about this condition, profound mysteries of this condition still need to be unraveled for which we have to go right up to molecular level to look for hidden ions. In the light of such a maze, the current endeavor is focused at giving better treatment for such patients so as to improve both maternal and perinatal outcome. Most patients of eclampsia are unbooked and belong to rural areas with very limited access to health services. Therefore, we should have a regime which can be given safely without much monitoring in these patients at such a center.
Until recently, major efforts by all obstetricians were to reduce maternal mortality in eclampsia. This has decreased from 25 to 37% in 1930s to less than 5% in India. Attention has now shifted to the fetus also. Many regimes have been tried so far, but magnesium sulfate (MgSO 4 ) stood the first of all. But this drug too is not free of complications. It is well known that MgSO 4 is the drug of choice to control seizures in women of eclampsia, but what is its lowest effective dose is a matter of debate.
The following discussion emphasizes role of lowdose MgSO 4 regime in patients of eclampsia to improve maternal and perinatal outcome.
MATERIALS AND METHODS
The present study was a prospective study conducted in the Department of Obstetrics and Gynecology, Mahatma Gandhi Medical College and Maharaja Yeshwantrao Hospital, Indore. Total 78 cases of eclampsia were included in the study. These cases were emergency cases in labor room irrespective of age and parity. Thirty-nine cases of eclampsia were given low-dose regimen and remaining 39 were given high-dose regimen (Pritchard regimen) . Patients with renal hypertension, coincidental seizures in pregnancy like epilepsy or any space occupying lesion or trauma to brain or hyperpyrexia, renal failure, and pulmonary edema were excluded.
Detailed history regarding age, parity, duration of pregnancy, history of pre-eclampsia, time of onest of first convulsion (to calculate number of convulsions), admission to delivery interval was taken. Magnesium sulfate was given for seizure control in eclampsia.
Protocol for Low-dose Regime in Eclampsia
Loading Dose A dose of 4 gm MgSO 4 given IV diluted in 20 cc D5 given slowly up to 5 to 8 minutes.
Maintenance Dose
A dose of 2 gm MgSO 4 IV similarly diluted. Start 3 hours after loading dose given 3 hourly for 24 hours after delivery or last seizures, whichever is later.
In Case of Recurrence of Convulsions
A dose of 2 gm IV is given, and previous regime is continued.
Pritchard Protocol for Eclampsia

Loading Dose
A dose of 4 gm MgSO 4 given IV, diluted in 20 cc D5 given slowly up to 5 to 8 minutes + 10 gm IM MgSO 4 .
Maintenance Dose
A dose of 5 gm MgSO 4 IM every 4 hourly. Start 4 hours after loading dose for 24 hours after delivery or last seizures, whichever is later.
All patients were monitored on clinical criteria. Before giving each dose of MgSO 4 toxicity was assessed in form of deep tendon reflexes, urine output, and respiratory rate; dose was deferred if urine output <100 mL in 4 hours, loss of knee jerk, RR < 16/minute. Antihypertensive was given if BP > 160/110. Termination of pregnancy was done in all cases of eclampsia. Delivery was expedited through induction/augmentation of labor with prostaglandin E2 and oxytocin with artificial rupture of membranes. Cesarean section was done in cases when convulsions were not controlled or in whom induction failed or if decision taken for obstetric indication.
RESULTS AND DISCUSSION
We included 79 cases of eclampsia with average weight profile 45 + 5.3 kg. Out of these, 48 (61.53%) were primigravida and 30 (38.47%) were multigravida. Seventy (89.74%) were antenatal eclampsia and eight (10.26%) were postnatal.
In their study, Biswas et al 2 found that most of the cases were primigravida. Sardesai 3 found that 73.67%
of patients of eclampsia were primigravida and 26.33% eclampsia were multigravida. In our study, we found that in women with low-dose regimen 37 (94.87%) women had control of convulsions and only 2 (5.13%) had recurrence of convulsions which were well controlled with 2 gm IV additional dose ( (Table 2 ). Thus, serum magnesium level was in the therapeutic range (3.5-8.4 μq/dL) in both the groups, but there was a significant difference in serum magnesium level in both the groups, but there was no statistical difference in control of convulsions in both groups. Thus, if similar results were obtained with low dose then extra high doses should be given, which only increase side effects and hence are not advantageous.
Average duration of labor in low-dose group was 7.742 hours as compared to 10.41 hours in the high-dose group (Table 3) . Magnesium sulfate inhibits uterine contraction, i.e., why it has a role in management of preterm labor. 5 Bhalla 6 found mean duration of labor with Pritchard regimen to be 11.4 hours, thus our results are comparable with the authors. With this observation, it is clear that complication like loss of knee jerk (2.56%) and oliguria (1.28%) were less in low-dose group. Recurrence of seizures was seen in two cases (5.13%), number of doses deferred in two cases (5.13%), and no woman required calcium gluconate In this study, we found that perinatal mortality was significantly less in low-dose group, i.e., 7 (20%), compared to high-dose group, i.e., 13 (37.14%). There were four stillbirths (11.43%), early neonatal death (ENND) three (8.57%), respiratory depression (Apgar at 5 minutes) three (8.57%), less hypotonia 4 (11.43%) in neonates of patients receiving low-dose regimen compared to other group (Table 5) . Also, no baby of the patients receiving low-dose MgSO 4 regimen required calcium gluconate in neonatal intensive care unit, while three babies of the patients receiving Pritchard regimen required calcium gluconate to combat magnesium overdose which occurred due to MgSO 4 given to their mothers. Concentration of magnesium in fetus and neonate are similar to maternal levels. This translates clinically into decreased fetal heart variability during labor and central nervous system depression in neonate. Infants of mothers treated with MgSO 4 shortly before delivery are frequently hypotonic at birth and require respiratory support, until the magnesium is eliminated.
Long-term use may cause fetal hypocalcemia. Recent investigations have suggested existence of an association between use of MgSO 4 in women of preterm labor and incidence of intraventricular hemorrhage, neonatal depression, neonatal hypocalcemia, and neonatal hypo tonia. These disadvantages are less in the patients receiving low-dose MgSO 4 regimen compared to patients receiving conventional Pritchard regimen. So, the women receiving low-dose MgSO 4 be limited in women who are known to be or appear to be small or low weight. Administering Pritchard regimen to them might prove to be hazardous with a possibility of respiratory failure. Patients of our setup are usually from low socioeconomic status with poor weight gain in pregnancy. Actually, even if we give Pritchard regimen, the excess of magnesium is excreted by the kidney. The question is then, why give extra salt when it is wasted? This is a strong justification for giving low-dose regimen.
CONCLUSION
Eclampsia most often affects primigravida and unbooked women.
• Control of convulsion by low-dose MgSO 4 regimen was nearly equal (94.87%) to the patients who were given Pritchard regimen (97.43%).
• Serum magnesium level was significantly less in patients receiving low dose compared to others. Thus, less monitoring of serum magnesium level is required in patients who were given low-dose MgSO 4 regimen.
• Average duration of labor in women of eclampsia was less in women who were given low-dose regimen compared to patients receiving Pritchard regimen.
• Toxicity of MgSO 4 (like oliguria, loss of knee jerk), was significantly less in women receiving low-dose regimen compared to patients receiving Pritchard regimen.
• Perinatal outcome is definitely better in women receiving low-dose MgSO 4 compared to the conventional Pritchard regimen. So, it is highly effective in reducing maternal and perinatal morbidity and mortality. In our study, we found that this low-dose MgSO 4 regimen is effective, as Pritchard regimen does not require monitoring and is associated with less side effects in mother and baby and with definitely better perinatal outcome. So, it should be given in all women of eclampsia so as to improve maternal and perinatal outcome in our patients.
